These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 29439172)

  • 1. Inflammatory Myofibroblastic Tumor Driven by Novel
    Rao N; Iwenofu H; Tang B; Woyach J; Liebner DA
    J Natl Compr Canc Netw; 2018 Feb; 16(2):115-121. PubMed ID: 29439172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib.
    Liu W; Duan Q; Gong L; Yang Y; Huang Z; Guo H; Niu X
    Invest New Drugs; 2021 Feb; 39(1):278-282. PubMed ID: 32915420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy-associated Inflammatory Myofibroblastic Tumors of the Uterus Are Clinically Distinct and Highly Enriched for TIMP3-ALK and THBS1-ALK Fusions.
    Devereaux KA; Fitzpatrick MB; Hartinger S; Jones C; Kunder CA; Longacre TA
    Am J Surg Pathol; 2020 Jul; 44(7):970-981. PubMed ID: 32271187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report.
    Takahashi A; Kurosawa M; Uemura M; Kitazawa J; Hayashi Y
    J Int Med Res; 2018 Aug; 46(8):3498-3503. PubMed ID: 29900760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.
    Lovly CM; Gupta A; Lipson D; Otto G; Brennan T; Chung CT; Borinstein SC; Ross JS; Stephens PJ; Miller VA; Coffin CM
    Cancer Discov; 2014 Aug; 4(8):889-95. PubMed ID: 24875859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
    Parker BM; Parker JV; Lymperopoulos A; Konda V
    J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory Myofibroblastic Tumor of the Bladder With FN1-ALK Gene Fusion: Different Response to ALK Inhibition.
    Reinhart S; Trachsel Y; Fritz C; Wagner U; Bode-Lesniewska B; John H; Pless M
    Urology; 2020 Dec; 146():32-35. PubMed ID: 33007314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
    Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
    Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE.
    Schöffski P; Kubickova M; Wozniak A; Blay JY; Strauss SJ; Stacchiotti S; Switaj T; Bücklein V; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Lee CJ; Speetjens FM; Nzokirantevye A; Neven A; Kasper B
    Eur J Cancer; 2021 Oct; 156():12-23. PubMed ID: 34392187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.
    Felkai L; Bánusz R; Kovalszky I; Sápi Z; Garami M; Papp G; Karászi K; Varga E; Csóka M
    Pathol Oncol Res; 2019 Jan; 25(1):217-224. PubMed ID: 29081033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
    Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
    Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial Response to Ceritinib in a Patient With Abdominal Inflammatory Myofibroblastic Tumor Carrying a TFG-ROS1 Fusion.
    Li Y; Chen X; Qu Y; Fan JM; Li Y; Peng H; Zheng Y; Zhang Y; Zhang HB
    J Natl Compr Canc Netw; 2019 Dec; 17(12):1459-1462. PubMed ID: 31805529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaplastic Lymphoma Kinase Mutation (
    Carneiro BA; Pamarthy S; Shah AN; Sagar V; Unno K; Han H; Yang XJ; Costa RB; Nagy RJ; Lanman RB; Kuzel TM; Ross JS; Gay L; Elvin JA; Ali SM; Cristofanilli M; Chae YK; Giles FJ; Abdulkadir SA
    Clin Cancer Res; 2018 Jun; 24(12):2732-2739. PubMed ID: 29559559
    [No Abstract]   [Full Text] [Related]  

  • 14. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
    Butrynski JE; D'Adamo DR; Hornick JL; Dal Cin P; Antonescu CR; Jhanwar SC; Ladanyi M; Capelletti M; Rodig SJ; Ramaiya N; Kwak EL; Clark JW; Wilner KD; Christensen JG; Jänne PA; Maki RG; Demetri GD; Shapiro GI
    N Engl J Med; 2010 Oct; 363(18):1727-33. PubMed ID: 20979472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
    Mossé YP; Voss SD; Lim MS; Rolland D; Minard CG; Fox E; Adamson P; Wilner K; Blaney SM; Weigel BJ
    J Clin Oncol; 2017 Oct; 35(28):3215-3221. PubMed ID: 28787259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
    Mansfield AS; Murphy SJ; Harris FR; Robinson SI; Marks RS; Johnson SH; Smadbeck JB; Halling GC; Yi ES; Wigle D; Vasmatzis G; Jen J
    Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uterine inflammatory myofibroblastic tumor: First report of a ROS1 fusion.
    Bennett JA; Wang P; Wanjari P; Diaz L; Oliva E
    Genes Chromosomes Cancer; 2021 Dec; 60(12):822-826. PubMed ID: 34322931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects.
    Brivio E; Zwaan CM
    Pediatr Blood Cancer; 2019 May; 66(5):e27645. PubMed ID: 30697903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature.
    Alan O; Kuzhan O; Koca S; Telli TA; Basoglu T; Ercelep O; Filinte D; Sengul Y; Arikan H; Kaya S; Babacan NA; Dane F; Yumuk PF
    J Oncol Pharm Pract; 2020 Jun; 26(4):1011-1018. PubMed ID: 31615346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "How long does crizotinib work? a rare case of recurrent inflammatory myofibroblastic tumor".
    Albayrak HC; Gürler F; Sütçüoğlu O; Akyürek N; Özet A
    Anticancer Drugs; 2022 Jan; 33(1):109-111. PubMed ID: 34261914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.